Clinical Trial Results:
A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid
Summary
|
|
EudraCT number |
2007-006658-24 |
Trial protocol |
GB DE |
Global end of trial date |
31 Oct 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Mar 2019
|
First version publication date |
10 Mar 2019
|
Other versions |
|
Summary report(s) |
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pe |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
08024
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN13704604 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University of Nottingham
|
||
Sponsor organisation address |
Research and Innovation, Jubilee Conference Centre, Triumph Road, Nottingham, United Kingdom, NG8 1DH
|
||
Public contact |
Professor Hywel Williams, University of Nottingham
, +44 1158231048, hywel.williams@nottingham.ac.uk
|
||
Scientific contact |
Ms Angela Shone, University of Nottingham
, +44 1158467906, sponsor@nottingham.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
16 Mar 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
31 Oct 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Oct 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
• To evaluate the effectiveness, safety and cost-effectiveness of a strategy of initiating BP
treatment with oral doxycycline or oral prednisolone. We hypothesised that starting treatment with
doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over
starting treatment with oral prednisolone.
|
||
Protection of trial subjects |
Trial oversight was by a Trial Steering Committee and an independent Data Monitoring Committee.
Ethics permission was granted for all participating sites.
|
||
Background therapy |
To reflect clinical practice additional application of potent topical corticosteroids (up to 30 g/week, preferably mometasone furoate) to affected areas (or if in the doxycycline arm a switch to oral corticosteroids if symptoms and blister control were inadequate) was permitted except between weeks 3 and 6. Moisturiser applied to blisters and erosions at any time was permitted. | ||
Evidence for comparator |
Oral prednisolone is thought to be effective at reducing the blisters in BP, but it has many side effects as indicated in previous trials comparing topical corticosteroids with oral corticosteroids (1-3). Doxycycline is perceived to be less effective but probably has fewer side effects. (1) Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002;346:321–7.http://dx.doi.org/10.1056/NEJMoa011592 (2) Joly P, Roujeau JC, Benichou J, Delaporte E, D’Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009;129:1681–7. http://dx.doi.org/10.1038/ jid.2008.412 (3) Fuertes de Vega I, Iranzo-Fernandez P, Mascaro-Galy JM. Bullous pemphigoid: clinical practiceguidelines. Actas Dermosifiliogr 2014;105:328–46. http://dx.doi.org/10.1016/j.ad.2012.10.022 | ||
Actual start date of recruitment |
02 Mar 2009
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 241
|
||
Country: Number of subjects enrolled |
Germany: 12
|
||
Worldwide total number of subjects |
253
|
||
EEA total number of subjects |
253
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
22
|
||
From 65 to 84 years |
167
|
||
85 years and over |
64
|
|
||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||
Recruitment details |
UK - 1st March 2009 - 31st October 2013 Germany - 1st February 2010 - 31st October 2013 | |||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||
Screening details |
Inclusion Adults capable of consent Clinical diagnosis of BP Min 3 significant blisters in past week (at least 2 body sites) Positive direct or indirect immunofluorescence No blisters/treatment for BP in past year Exclusion Systemic medication for current BP Oral prednisolone/doxycycline past 12 weeks Mostly/entirely mucosal pemphigoid | |||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||
Period 1 title |
Weeks 0 to 6
|
|||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Data analyst | |||||||||||||||||||||||||||
Blinding implementation details |
Investigator and analyst blinded to the treatment allocation for this period
|
|||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Intervention: doxycycline | |||||||||||||||||||||||||||
Arm description |
200 mg/day of doxycycline taken as a single, daily dose (brand not specified). | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Doxycycline
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
200 mg/day of doxycycline taken as a single, daily dose (brand not specified).
|
|||||||||||||||||||||||||||
Arm title
|
Comparator: prednisolone | |||||||||||||||||||||||||||
Arm description |
0.5 mg/kg/day of prednisolone taken as a single, daily dose (brand not specified). | |||||||||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||||||||
Investigational medicinal product name |
Prednisolone
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
0.5 mg/kg/day of prednisolone taken as a single, daily dose (brand not specified).
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Period 2
|
||||||||||||||||||||||||||||
Period 2 title |
Weeks 7 to 52
|
|||||||||||||||||||||||||||
Is this the baseline period? |
No | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Intervention: doxycycline | |||||||||||||||||||||||||||
Arm description |
200 mg/day of doxycycline taken as a single, daily dose (brand not specified). | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Doxycycline
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
200 mg/day of doxycycline taken as a single, daily dose (brand not specified).
|
|||||||||||||||||||||||||||
Arm title
|
Comparison: prednisolone | |||||||||||||||||||||||||||
Arm description |
0.5 mg/kg/day of prednisolone taken as a single, daily dose (brand not specified). | |||||||||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||||||||
Investigational medicinal product name |
Prednisolone
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
0.5 mg/kg/day of prednisolone taken as a single, daily dose (brand not specified).
|
|||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Intervention: doxycycline
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
200 mg/day of doxycycline taken as a single, daily dose (brand not specified). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Comparator: prednisolone
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
0.5 mg/kg/day of prednisolone taken as a single, daily dose (brand not specified). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Period 1 Difference pred-doxy week 6 success
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Modified intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Non-inferiority comparison, week 6. Treatment success defined as 3 or fewer blisters at week 6 regardless of treatment modification. Percentage difference between prednislone and doxycylcine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Primary Safety outcome: proportion difference
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Modified intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Superiority comparison. The proportion of participants with grade 3 (severe), 4 (life-threatening) and
5 (death) adverse events that were possibly, probably or definitely related to the treatment in the
52 weeks following randomisation, comparison prednisolone - doxycycline.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Intervention: doxycycline
|
||
Reporting group description |
200 mg/day of doxycycline taken as a single, daily dose (brand not specified). | ||
Reporting group title |
Comparator: prednisolone
|
||
Reporting group description |
0.5 mg/kg/day of prednisolone taken as a single, daily dose (brand not specified). | ||
Reporting group title |
Intervention: doxycycline
|
||
Reporting group description |
200 mg/day of doxycycline taken as a single, daily dose (brand not specified). | ||
Reporting group title |
Comparison: prednisolone
|
||
Reporting group description |
0.5 mg/kg/day of prednisolone taken as a single, daily dose (brand not specified). | ||
Subject analysis set title |
Period 1 Difference pred-doxy week 6 success
|
||
Subject analysis set type |
Modified intention-to-treat | ||
Subject analysis set description |
Non-inferiority comparison, week 6. Treatment success defined as 3 or fewer blisters at week 6 regardless of treatment modification. Percentage difference between prednislone and doxycylcine
|
||
Subject analysis set title |
Primary Safety outcome: proportion difference
|
||
Subject analysis set type |
Modified intention-to-treat | ||
Subject analysis set description |
Superiority comparison. The proportion of participants with grade 3 (severe), 4 (life-threatening) and
5 (death) adverse events that were possibly, probably or definitely related to the treatment in the
52 weeks following randomisation, comparison prednisolone - doxycycline.
|
|
||||||||||
End point title |
Primary endpoint: Three or less blisters at 6 weeks | |||||||||
End point description |
Proportion of participants who achieved treatment success (three or less blisters) at 6 weeks
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Treatment success at 6 weeks
|
|||||||||
|
||||||||||
Statistical analysis title |
Difference in proportions: prednis - doxycycli | |||||||||
Comparison groups |
Intervention: doxycycline v Comparator: prednisolone
|
|||||||||
Number of subjects included in analysis |
213
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
non-inferiority | |||||||||
Method |
||||||||||
Parameter type |
Mean difference (final values) | |||||||||
Point estimate |
18.7
|
|||||||||
Confidence interval |
||||||||||
level |
90% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
9.8 | |||||||||
upper limit |
27.6 | |||||||||
Variability estimate |
Standard error of the mean
|
|
|||||||||||||
End point title |
Primary endpoint: proportion of grade 3 or above AEs 52 weeks | ||||||||||||
End point description |
Grade 3, 4 and 5 side effects (treatment-related severe, life-threatening or fatal (as per CTC criteria) v3.0 by 52 weeks
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
52 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Primary o/c: period 2, week 52, superiorty compar | ||||||||||||
Comparison groups |
Intervention: doxycycline v Comparison: prednisolone v Primary Safety outcome: proportion difference
|
||||||||||||
Number of subjects included in analysis |
447
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.004 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
18.4
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
6 | ||||||||||||
upper limit |
30.85 |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
0-52
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
1
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Individual adverse vents were not reported. Grade categorisation of all adverse events were collected and analysed as part of the primary safety outcome. Details in the attached summary paper. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |